共 50 条
- [41] First-line HLX07 vs. placebo combined with serplulimab and chemotherapy for nasopharyngeal cancer: A randomised, double-blind, multicentre phase II studyANNALS OF ONCOLOGY, 2024, 35Zhang, L.Fang, W. F. .Ai, X.Lei, F.Ma, D.Ni, H.Hou, X.Wang, Q.Yu, H.Li, J.
- [42] FINAL RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PHASE III STUDY OF SUNITINIB PLUS FOLFIRI VS. PLACEBO PLUS FOLFIRI IN FIRST-LINE TREATMENT OF PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)ANNALS OF ONCOLOGY, 2010, 21 : 19 - 19Carrato, A.Swieboda-Sadlej, A.Staszewska-Skurczynska, M.Lim, R.Roman, L.Shparyk, Y.Bondarenko, I.Lin, X.Lechuga, M. J.Tursi, J. M.Sun, Y.De la Cruz, J. A.Jonker, D.Van Cutsem, E.
- [44] Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapyBreast Cancer Research and Treatment, 2010, 124 : 177 - 186Mark ClemonsAnil A. JoyRadhi AbdulnabiMauricio KotliarJodi LynchJohan P. JordaanNeill IscoeKaren Gelmon
- [45] A randomized, double-blind, phase 3 trial of MK-7684A plus chemotherapy versus pembrolizumab plus chemotherapy as first-line therapy for metastatic non-small cell lung cancer (NSCLC): KeyVibe-007.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Garassino, Marina ChiaraFelip, EnriquetaAwad, Mark M.Wang, WeiKim, Sung JinPietanza, Maria CatherineRodriguez-Abreu, Delvys
- [46] Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapyBREAST CANCER RESEARCH AND TREATMENT, 2010, 124 (01) : 177 - 186Clemons, MarkJoy, Anil A.Abdulnabi, RadhiKotliar, MauricioLynch, JodiJordaan, Johan P.Iscoe, NeillGelmon, Karen
- [47] Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trialLANCET ONCOLOGY, 2023, 24 (10): : 1094 - 1108Saad, FredClarke, Noel W.Oya, MototsuguShore, NealProcopio, GiuseppeGuedes, Joao DanielArslan, CagatayMehra, NivenParnis, FrancisBrown, EmmaSchlurmann, FriederikeJoung, Jae YoungSugimoto, MikioSartor, OliverLiu, Yu-ZhenPoehlein, ChristianBarker, Lauradel Rosario, Paula MichelleArmstrong, Andrew J.
- [48] AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trialJOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Schmid, PeterAbraham, JacintaChan, StephenWheatley, DuncanBrunt, MurrayNemsadze, GiaBaird, RichardPark, Yeon HeeHall, PeterPerren, TimothyStein, Robert C.Laszlo, MangelFerrero, Jean-MarcPhillips, MelissaConibear, JohnSarker, Shah-JalalPrendergast, AaronCartwrightx, HayleyMousa, KellyTurner, Nicholas C.
- [49] Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancerCANCER RESEARCH, 2022, 82 (04)Cortes, JavierCescon, David W.Rugo, Hope S.Nowecki, ZbigniewIm, Seock-AhYusof, Mastura MdGallardo, CarlosLipatov, OlegBarrios, Carlos HenriquePerez-Garcia, JoseIwata, HirojiMasuda, NorikazuOtero, Marco TorregrozaGokmen, ErhanLoi, ShereneGuo, ZifangZhou, XuanKarantza, VassilikiPan, WilburSchmid, Peter
- [50] Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trialLANCET ONCOLOGY, 2023, 24 (11): : 1181 - 1195Rha, Sun YoungOh, Do-YounYanez, PatricioBai, YuxianRyu, Min-HeeLee, JeeyunRivera, FernandoAlves, Gustavo VasconcelosGarrido, MarceloShiu, Kai-KeenFernandez, Manuel GonzalezLi, JinLowery, Maeve A.Cil, TimucinCruz, Felipe MeloQin, ShukuiLuo, SuxiaPan, HongmingWainberg, Zev A.Yin, LinaBordia, SonalBhagia, PoojaWyrwicz, Lucjan S.